Aadi Bioscience, Inc. (AADI) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Pacific Palisades, CA, United States. El CEO actual es David J. Lennon.
AADI tiene fecha de IPO 2018-02-16, 53 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $94.89M.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
